Principal Financial Group Inc. grew its stake in Eli Lilly And Co (NYSE:LLY) by 17.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,734,994 shares of the company’s stock after purchasing an additional 255,461 shares during the quarter. Principal Financial Group Inc. owned about 0.16% of Eli Lilly And Co worth $200,773,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. grew its position in shares of Eli Lilly And Co by 1.6% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock worth $641,000 after buying an additional 87 shares during the period. Maple Capital Management Inc. grew its position in Eli Lilly And Co by 0.5% during the 4th quarter. Maple Capital Management Inc. now owns 99,805 shares of the company’s stock valued at $11,549,000 after purchasing an additional 470 shares during the last quarter. Avalon Advisors LLC grew its position in Eli Lilly And Co by 32.4% during the 4th quarter. Avalon Advisors LLC now owns 131,108 shares of the company’s stock valued at $15,172,000 after purchasing an additional 32,068 shares during the last quarter. Marsico Capital Management LLC purchased a new stake in Eli Lilly And Co during the 4th quarter valued at about $34,820,000. Finally, L & S Advisors Inc purchased a new stake in Eli Lilly And Co during the 4th quarter valued at about $3,812,000. 79.58% of the stock is currently owned by hedge funds and other institutional investors.
In other Eli Lilly And Co news, SVP Aarti S. Shah sold 1,800 shares of the firm’s stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $125.85, for a total transaction of $226,530.00. Following the sale, the senior vice president now owns 18,425 shares in the company, valued at approximately $2,318,786.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. Insiders sold a total of 989,224 shares of company stock worth $123,587,253 in the last quarter. Company insiders own 0.11% of the company’s stock.
Shares of NYSE:LLY opened at $124.08 on Tuesday. Eli Lilly And Co has a twelve month low of $77.09 and a twelve month high of $132.13. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $129.63 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 2.37 and a beta of 0.33.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter last year, the company earned $1.14 EPS. Eli Lilly And Co’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/16/principal-financial-group-inc-acquires-255461-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.